FDA Approves Koselugo for Pediatric Neurofibromatosis Type 1
TUESDAY, April 14, 2020 -- Koselugo (selumetinib) has received the first approval for treatment of neurofibromatosis type 1 (NF1) in children ages 2 years and older, the U.S. Food and Drug Administration announced Friday.
Approved specifically for...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Brain | Children | Food and Drug Administration (FDA) | General Medicine | Neurofibromatosis | Neurology | Pediatrics